US Biosimilar Fee Collections Fall Short
The FDA Has Modified Its Carryover Spend-Down Plan
Executive Summary
A lower-than-expected number of fee-paying application submissions in FY 2018 resulted in the agency spending approximately $9.7m more than anticipated from its user fee carryover balance, leading to a reset of spend-down targets for the remainder of BsUFA II.